<DOC>
	<DOCNO>NCT01507272</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial ass safety tolerability ( maximum tolerate dose ) five ascend single dos NNC 90-1170 ( liraglutide ) .</brief_summary>
	<brief_title>Safety Tolerability Liraglutide Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male subject ethnic origin Written inform consent obtain . ( The subject must give sign informed consent trialrelated activity . Trialrelated activity procedure would perform normal management subject ) Good general health base medical history , physical laboratory examination , incl . ECG ( electrocardiogram ) Body mass index within range 2027 kg/m^2 , inclusive Any clinically significant abnormal laboratory test result clinically significant abnormal ECG History alcoholism drug addiction ; positive result plasma urine screen illicit drug Alcohol intake within 48 hour visit Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody HIV ( human immunodeficiency virus ) antibodies History significant drug allergy drug hypersensitivity Smoke 5 cigarette , equivalent per day unable refrain smoke 3 day prior dose day confinement period Subjects drink 8 cup tea/coffee per day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>